Effects of cannabis

INDVR Brands Inc. Announces Filling of Annual Financials Statements and Grants Incentive Stock Options

Retrieved on: 
Tuesday, June 1, 2021
Cannabis smoking, Herbalism, Medicinal plants, Psychoactive drugs, Health sciences, Communication, Forward-looking statement, Articles, Cannabis, Effects of cannabis, Medical cannabis

The Company assumes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Key Points: 
  • The Company assumes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
  • Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking information.
  • Cannabis is legal in certain States in the United States ("U.S."), however cannabis remains illegal under U.S. federal laws.
  • Any such proceedings brought against INDVR Brands may materially adversely affect its operations and financial performance in the U.S. market.

Sugarbud Craft Growers Corp. to Present Live at the Benzinga Virtual Cannabis Capital Conference and Announces the Launch of Two New High-Potency Strains

Retrieved on: 
Monday, May 31, 2021
Euphoriants, Entheogens, Medicinal plants, Psychoactive drugs, Branches of biology, Drugs, Herbalism, Cannabis smoking, Cannabis, Medical cannabis, Effects of cannabis, Tetrahydrocannabinol

Both strains are distinct high-potency, high-terpene phenotypes with a total THC range between 20-25% and terpene profles between 2-5%.

Key Points: 
  • Both strains are distinct high-potency, high-terpene phenotypes with a total THC range between 20-25% and terpene profles between 2-5%.
  • Like Mule Fuel, Sugarbud Krypto Chronic #2 was phenotyped from the Companys extensive genetic library and is exclusive to Sugarbud.
  • Benzinga's virtual Cannabis Capital Conference is guaranteed to offer participants all the benefits of an immersive and robust in-person conference from any remote location.
  • The Conference will feature an interactive forum of live presentations from top CEOs, investors, and leaders in the cannabis space.

HEXO Corp announces acquisition of Redecan to create Canadian market leader in adult-use sales

Retrieved on: 
Friday, May 28, 2021
Entheogens, Euphoriants, Medicinal plants, Cannabis smoking, Psychoactive drugs, Cannabis, Effects of cannabis

We articulated a plan to become a top three cannabis player in the Canadian adult-use market, said HEXO CEO and co-founder Sebastien St-Louis.

Key Points: 
  • We articulated a plan to become a top three cannabis player in the Canadian adult-use market, said HEXO CEO and co-founder Sebastien St-Louis.
  • On behalf of our entire management team, I look forward to warmly welcoming the Redecan team to the HEXO family, continued St-Louis.
  • Joining the HEXO team will leverage our combined strengths and accelerate our growth within Canada and internationally, added Redecan co-founder Pete Montour.
  • Robust product portfolio: Following the Transaction, HEXO will be a Canadian volume leader in dried flower across premium, mainstream and value price points.

Glow LifeTech Secures Canadian Processing Facility, Begins Build-out to Produce Next-Generation Cannabis Ingredients

Retrieved on: 
Friday, May 28, 2021
Cannabis smoking, Psychoactive drugs, Cannabis, Entheogens, Euphoriants, Effects of cannabis, Glow, Hemp

Toronto, Ontario--(Newsfile Corp. - May 28, 2021) - Glow LifeTech Corp. (CSE: GLOW) (FSE: 9DO) ("Glow" or the "Company"), a biotech innovator producing next-generation, science-backed natural ingredients, is pleased to report that the Company has commenced the build-out and commissioning of licensed processing space ("Processing Space") to bring a suite of fast-acting, high-absorption, water-soluble cannabis-based ingredients to the Canadian market.

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - May 28, 2021) - Glow LifeTech Corp. (CSE: GLOW) (FSE: 9DO) ("Glow" or the "Company"), a biotech innovator producing next-generation, science-backed natural ingredients, is pleased to report that the Company has commenced the build-out and commissioning of licensed processing space ("Processing Space") to bring a suite of fast-acting, high-absorption, water-soluble cannabis-based ingredients to the Canadian market.
  • The Processing Space is licensed for the processing and sale of cannabis under the Canadian Cannabis Act.
  • Initial MyCell ingredients include THC, CBD, CBN, isolates and cannabis derived terpenes at the facility.
  • With its proprietary technology, this Collaboration Agreement provides Glow the necessary production capacity to supply Canada nationally, across both adult-use and medical markets.

Khiron Life Sciences Reports First Quarter 2021 Financial Results

Retrieved on: 
Thursday, May 27, 2021
Cannabis smoking, Psychoactive drugs, Cannabis, Entheogens, Herbalism, Effects of cannabis

With continued month-over-month growth, Q2 2021 continues to build on the achievements of Q1 2021.

Key Points: 
  • With continued month-over-month growth, Q2 2021 continues to build on the achievements of Q1 2021.
  • In March 2021, Khiron commenced sales in Germany with the successful delivery of EU-GMP medical cannabis products.
  • In April 2021, the Company introduced Khiron 1/14 (High CBD flower) in addition to 5-gram jars of flower products.
  • Khiron undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable).

Khiron Life Sciences Reports First Quarter 2021 Financial Results

Retrieved on: 
Thursday, May 27, 2021
Cannabis smoking, Psychoactive drugs, Cannabis, Entheogens, Herbalism, Effects of cannabis

With continued month-over-month growth, Q2 2021 continues to build on the achievements of Q1 2021.

Key Points: 
  • With continued month-over-month growth, Q2 2021 continues to build on the achievements of Q1 2021.
  • In March 2021, Khiron commenced sales in Germany with the successful delivery of EU-GMP medical cannabis products.
  • In April 2021, the Company introduced Khiron 1/14 (High CBD flower) in addition to 5-gram jars of flower products.
  • Khiron undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable).

GROW.HOUSE Launching the First Ever NFT game to Grow Digital Cannabis and Earn Cryptocurrency

Retrieved on: 
Thursday, May 27, 2021
Cryptocurrencies, Blockchains, Video gaming, Health sciences, Facebook games, Social casual games, Decentralized finance, Ethereum, Non-fungible token, Medical cannabis, FarmVille, Effects of cannabis

MIAMI, May 27, 2021 /PRNewswire/ -- Launching the first ever digital metaverse for lovers of Cannabis, Crypto, and DeFi.

Key Points: 
  • MIAMI, May 27, 2021 /PRNewswire/ -- Launching the first ever digital metaverse for lovers of Cannabis, Crypto, and DeFi.
  • GROW.HOUSE is a decentralized cannabis NFT game that educates users about cannabis and cryptocurrencies, in a fun Farmvill-esque world, through growing digital cannabis.
  • GROW.HOUSE is a Farmville-like game, where users can grow digital cannabis, earn $GROW tokens, collect NFTs, and learn about yield farming.
  • Within the game users can plant NFT cannabis flowers, earn $GROW tokens, and use in-game assets to beautify farms.

Ayurcann Expansion Continues with New Partnership

Retrieved on: 
Thursday, May 27, 2021
Medicinal plants, Entheogens, Euphoriants, Psychoactive drugs, Cannabis smoking, Herbalism, Health sciences, Branches of biology, Cannabis, Hemp, Effects of cannabis, Medical cannabis

Ayurcann is focused on becoming the partner of choice for leading Canadian cannabis brands by providing best-in-class, proprietary services including ethanol extraction, formulation, product development and custom manufacturing.

Key Points: 
  • Ayurcann is focused on becoming the partner of choice for leading Canadian cannabis brands by providing best-in-class, proprietary services including ethanol extraction, formulation, product development and custom manufacturing.
  • Joints Cannabis is a leading Canadian brand of premium CBD health and wellbeing products manufactured with care, craft with quality all-natural Canadian hemp-derived CBD.
  • It includes having good mental health, high life satisfaction, a sense of meaning or purpose, and the ability to manage stress.
  • This press release contains forward looking statements, including but not limited to statements relating to the Companys expansion plans and future production capacity.

REPEAT -- MediPharm Labs Launches High-CBD Wellness Oils in Quebec; Ships First Order of CBD 25 and CBD 50 Formulas Now Available for Retail Sale by SQDC

Retrieved on: 
Thursday, May 27, 2021
Drugs, Psychoactive drugs, Cannabis smoking, Cannabis, Euphoriants, Cannabinoids, Herbalism, Cannabidiol, Effects of cannabis

With our expanded footprint, we are now bringing our quality products to 95% of the retail market in Canada.

Key Points: 
  • With our expanded footprint, we are now bringing our quality products to 95% of the retail market in Canada.
  • MediPharm shipped its first order of its own MediPharm branded CBD oils - CBD 25 Regular Formula and CBD 50 Plus Formula - that will be for sale through the Socit qubcoise du cannabis (SQDC) retail outlets and e-commerce platform.
  • As a global leader, MediPharm Labs has completed commercial exports to Australia and has fully commercialized its Australian extraction facility.
  • Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.

Auxly Reaches an Agreement With Myconic Capital to Sell KGK Science For Up to $16.5 Million in Value

Retrieved on: 
Thursday, May 27, 2021
Cannabis smoking, Herbalism, Medicinal plants, Psychoactive drugs, Articles, Cannabis, Entheogens, Effects of cannabis, Brand, Medical cannabis, Value proposition

KGK is an outstanding CRO that knows how to unlock value in emerging industries through clinical work and will be an excellent fit with the team at Myconic.

Key Points: 
  • KGK is an outstanding CRO that knows how to unlock value in emerging industries through clinical work and will be an excellent fit with the team at Myconic.
  • About Auxly Cannabis Group Inc. (TSX: XLY)
    Auxly is a vertically integrated cannabis company dedicated to bringing branded cannabis products to market that consumers love and trust.
  • We build powerful value propositions with brands that connect and products that deliver on our consumer promise of quality, safety and efficacy.
  • Learn more at www.auxly.com and stay up to date at Twitter: @AuxlyGroup;Instagram: @auxlygroup;Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.